0001062993-23-001274.txt : 20230123 0001062993-23-001274.hdr.sgml : 20230123 20230123194928 ACCESSION NUMBER: 0001062993-23-001274 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230119 FILED AS OF DATE: 20230123 DATE AS OF CHANGE: 20230123 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Lake Ryan David CENTRAL INDEX KEY: 0001450325 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36329 FILM NUMBER: 23545596 MAIL ADDRESS: STREET 1: KENSEY NASH CORPORATION STREET 2: 735 PENNSYLVANIA DRIVE CITY: EXTON STATE: PA ZIP: 19341 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Societal CDMO, Inc. CENTRAL INDEX KEY: 0001588972 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 261523233 STATE OF INCORPORATION: PA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1 E. UWCHLAN AVE, SUITE 112 CITY: EXTON STATE: PA ZIP: 19341 BUSINESS PHONE: 770-534-8239 MAIL ADDRESS: STREET 1: 1 E. UWCHLAN AVE, SUITE 112 CITY: EXTON STATE: PA ZIP: 19341 FORMER COMPANY: FORMER CONFORMED NAME: Recro Pharma, Inc. DATE OF NAME CHANGE: 20131010 4 1 form4.xml STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES X0306 4 2023-01-19 0001588972 Societal CDMO, Inc. SCTL 0001450325 Lake Ryan David C/O SOCIETAL CDMO, INC. 1 E. UWCHLAN AVE, SUITE 112 EXTON PA 19341 0 1 0 0 Chief Financial Officer Common Stock 2023-01-19 4 A 0 84848 A 596116 D Common Stock 2023-01-19 4 F 0 28374 1.35 D 567742 D Common Stock 2023-01-19 4 A 0 230944 0.00 A 798686 D Common Stock 2023-01-20 4 F 0 14438 1.36 D 784248 D Stock Option (Right to Buy) 1.35 2023-01-19 4 A 0 160929 0.00 A 2033-01-19 Common Stock 160929 160929 D On January 19, 2023, the Compensation Committee of the Board of Directors of the Company determined that performance-vesting criteria were met with regard to 84,848 performance-based restricted stock units granted in a prior year, which were converted into 84,848 shares of common stock on a one-for-one basis. Shares withheld by the Company to satisfy applicable withholding taxes upon vesting of the performance-based restricted stock units. Subject to shareholders approving an increase in the number of authorized shares of common stock at the Company's 2023 annual meeting of shareholders, these restricted stock units will vest in four equal annual installments beginning on January 19, 2024, subject to continued service with the Company. Shares withheld by the Company to satisfy applicable withholding taxes upon vesting of restricted stock units. Subject to shareholders approving an increase in the number of authorized shares of common stock at the Company's 2023 annual meeting of shareholders, the stock option vests in equal monthly installments over 48 months, beginning on February 19, 2023, subject to continued service with the Company. /s/ Ryan D. Lake 2023-01-23